Many laboratories are now performing BRCA1/BRCA2 testing in formalin-fixed paraffin-embedded (FFPE) tumor samples to detect germline and somatic variants to identify, in a single test, those patients with somatic and germline variants who are most likely to benefit from PARPi therapy. Here, BRCA1 is linked to neoplasm.